Molecular weight dependency of the acquired anticomplementary and anticoagulant activities of specifically substituted dextrans

Sulphated polysaccharides derived from dextran: biomaterials for vascular therapy

“…The nature and distribution of chemical groups and the composition can be altered, leading to polymers which mimic the action of heparin in diþerent biological systems. 3,19,40,41 In addition to anticoagulant activities, derivatized dextrans have the capacity to inhibit SMC growth and stimulate EC proliferation. With the examples of bioactive derivates described in this study, we propose that CMDBS could be considered as new interesting macromolecular drugs for vascular therapy.…”

CMDBS, Functional Analogue of Heparin Sulfate as a New Class of Corneal Ulcer Healing Agents

“…France). The specific anticoagulant activity of the dextran deriva tive (lU/mg of polymer) determined as previously described [20,21] is 4 IU/mg compared to a standard heparin (batch 108, Sanofi-Choay Recherches, Gentilly, France) with an anticoagulant activity of 173 IU/ mg.…”

Vascular Endothelial Growth Factor 165 (VEGF165) Activities Are Inhibited by Carboxymethyl Benzylamide Dextran That Competes for Heparin Binding to VEGF165 and VEGF165·KDR Complexes

“…Its chemical derivatization involves statistical distribution of chemical groups linked to the 1-6 glucosyl units forming the macromolecular chains (23). CMDB7 mimics some properties of heparin, such as the inter-actions with angiogenic growth factors, including FGF2 (24,25), transforming growth factor ␤, and platelet-derived growth factor (26), but it has no anticoagulant or anticomplement effects (27,28). We have shown that CMDB7 specifically inhibits the mitogenic effect and receptor binding of FGF2, plateletderived growth factor, and transforming growth factor ␤, and thus prevents the endothelial cell proliferation and migration as observed in vitro (25).…”